Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors


GÜMÜŞ M., Bilici A., Odabas H., Ustaalioglu B. B. O., Kandemir N., Demirci U., ...More

WORLD JOURNAL OF UROLOGY, vol.35, no.7, pp.1103-1110, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 7
  • Publication Date: 2017
  • Doi Number: 10.1007/s00345-016-1964-6
  • Journal Name: WORLD JOURNAL OF UROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1103-1110
  • Karadeniz Technical University Affiliated: Yes

Abstract

Background Currently, it is accepted that risk assessment of clinical stage I (CS I) nonseminomatous germ cell tumors (NSGCT) patient is mainly dependent on the presence of lymphovascular invasion (LVI). Initial active surveillance, adjuvant chemotherapy and retroperitoneal lymph node dissection (RPLND) are acceptable treatment options for these patients, but there is no uniform consensus. The purpose of this study was to compare outcomes of active surveillance with adjuvant chemotherapy.